Miraculins Inc. (Miraculins) is a Canada-based medical diagnostic development company focused on acquiring and advancing non-invasive tests for unmet clinical needs. The Company�s PreVu Non-Invasive Skin Cholesterol Test (PreVu) test is a coronary artery disease (CAD) risk assessment technology that measures cholesterol levels in a patient�s skin non-invasively and without the need for fasting. The Company's two primary technology programs are in the areas of cardiovascular disease and maternal health. As of February 8, 2012, the Company�s preeclampsia program was being advanced in partnership with Alere, Inc., a diagnostic company. In August 2013, Miraculins Inc acquired all relevant assets, including intellectual property, licenses and regulatory approvals, inventories, data and marketing materials, relating to the SCOUT DS technology from VeraLight Inc.